Literature DB >> 25469237

Epigenetic modifications in human thyroid cancer.

Bita Faam1, Mohammad Ali Ghaffari2, Ata Ghadiri3, Fereidoun Azizi4.   

Abstract

Thyroid carcinoma is the most common endocrine malignancy of the endocrine organs, and its incidence rate has steadily increased over the last decade. Over 95% of thyroid carcinoma is derived from follicular cells that have a spectrum of differentiation to the most invasive malignancy. The molecular pathogenesis of thyroid cancer remains to be clarified, although activating the RET, RAS and BRAF oncogenes have been well characterized. Increasing evidence from previous studies demonstrates that acquired epigenetic abnormalities participating with genetic alteration results in altered patterns of gene expression/function. Aberrant DNA methylation has been established in the CpG regions and microRNAs (miRNAs) expression profile recognized in cancer development. In the present review, a literature review was performed using MEDLINE and PubMed with the terms 'epigenetic patterns in thyroid cancer [or papillary thyroid carcinoma (PTC), follicular thyroid carcinoma (FTC), medullary thyroid cancer (MTC), anaplastic thyroid cancer (ATC)]', 'DNA methylation in thyroid cancer (or PTC, FTC, MTC, ATC)', 'miRNA expression in thyroid cancer (or PTC, FTC, MTC, ATC)', 'epigenetic patterns in cancer' and the current understanding of epigenetic patterns in thyroid cancer was discussed.

Entities:  

Keywords:  DNA methylation; epigenetic; microRNA; thyroid cancer

Year:  2014        PMID: 25469237      PMCID: PMC4251143          DOI: 10.3892/br.2014.375

Source DB:  PubMed          Journal:  Biomed Rep        ISSN: 2049-9434


  68 in total

1.  Chromosomal instability and tumors promoted by DNA hypomethylation.

Authors:  Amir Eden; François Gaudet; Alpana Waghmare; Rudolf Jaenisch
Journal:  Science       Date:  2003-04-18       Impact factor: 47.728

2.  Activin A and activin receptors in thyroid cancer.

Authors:  K M Schulte; C Jonas; R Krebs; H D Röher
Journal:  Thyroid       Date:  2001-01       Impact factor: 6.568

3.  Impact of pathognomonic genetic alterations on the prognosis of papillary thyroid carcinoma. ESES vienna presentation.

Authors:  Thomas J Musholt; Sonja Schönefeld; Christina H Schwarz; Felix M Watzka; Petra B Musholt; Christian Fottner; Matthias M Weber; Erik Springer; Arno Schad
Journal:  Langenbecks Arch Surg       Date:  2010-07-18       Impact factor: 3.445

4.  The role of microRNA genes in papillary thyroid carcinoma.

Authors:  Huiling He; Krystian Jazdzewski; Wei Li; Sandya Liyanarachchi; Rebecca Nagy; Stefano Volinia; George A Calin; Chang-Gong Liu; Kaarle Franssila; Saul Suster; Richard T Kloos; Carlo M Croce; Albert de la Chapelle
Journal:  Proc Natl Acad Sci U S A       Date:  2005-12-19       Impact factor: 11.205

Review 5.  Poorly differentiated and anaplastic thyroid cancer.

Authors:  Kepal N Patel; Ashok R Shaha
Journal:  Cancer Control       Date:  2006-04       Impact factor: 3.302

6.  MicroRNA profiling of sporadic and hereditary medullary thyroid cancer identifies predictors of nodal metastasis, prognosis, and potential therapeutic targets.

Authors:  Deepak Abraham; Nicole Jackson; Justin S Gundara; JingTing Zhao; Anthony J Gill; Leigh Delbridge; Bruce G Robinson; Stan B Sidhu
Journal:  Clin Cancer Res       Date:  2011-05-27       Impact factor: 12.531

7.  PTEN promoter methylation in sporadic thyroid carcinomas.

Authors:  Francisco Alvarez-Nuñez; Elena Bussaglia; Didac Mauricio; Juan Ybarra; Monica Vilar; Enrique Lerma; Alberto de Leiva; Xavier Matias-Guiu
Journal:  Thyroid       Date:  2006-01       Impact factor: 6.568

Review 8.  RET/PTC rearrangement in thyroid tumors.

Authors:  Yuri E Nikiforov
Journal:  Endocr Pathol       Date:  2002       Impact factor: 3.943

9.  The role of epigenetic alterations in papillary thyroid carcinogenesis.

Authors:  Ogechukwu P Eze; Lee F Starker; Tobias Carling
Journal:  J Thyroid Res       Date:  2011-06-14

10.  Analysis of loss of heterozygsity effect on thyroid tumor with oxyphilia cell locus in familial non medullary thyroid carcinoma in Iranian families.

Authors:  Hasti Atashi Shirazi; Mehdi Hedayati; Maryam Sadat Daneshpour; Abdollah Shafiee; Fereidoun Azizi
Journal:  Indian J Hum Genet       Date:  2012-09
View more
  17 in total

Review 1.  Genetic-guided Risk Assessment and Management of Thyroid Cancer.

Authors:  Mingzhao Xing
Journal:  Endocrinol Metab Clin North Am       Date:  2019-03       Impact factor: 4.741

2.  Expression of Hypoxia-Associated Protein HIF-1α in Follicular Thyroid Cancer is Associated with Distant Metastasis.

Authors:  Aumayr Klaus; Osmen Fathi; Traub-Weidinger Tatjana; Niederle Bruno; Koperek Oskar
Journal:  Pathol Oncol Res       Date:  2017-05-04       Impact factor: 3.201

3.  Mps1 is associated with the BRAFV600E mutation but does not rely on the classic RAS/RAF/MEK/ERK signaling pathway in thyroid carcinoma.

Authors:  Yike Li; Yanyan Zhang; Shuaishuai Xiao; Pengzhou Kong; Caixia Cheng; Ruyi Shi; Fang Wang; Ling Zhang; Juan Wang; Zhiwu Jia; Shuai Wu; Yun Liu; Jiansheng Guo; Xiaolong Cheng; Yongping Cui; Jing Liu
Journal:  Oncol Lett       Date:  2018-04-24       Impact factor: 2.967

4.  Dual Inhibition of HDAC and Tyrosine Kinase Signaling Pathways with CUDC-907 Inhibits Thyroid Cancer Growth and Metastases.

Authors:  Shweta Kotian; Lisa Zhang; Myriem Boufraqech; Kelli Gaskins; Sudheer Kumar Gara; Martha Quezado; Naris Nilubol; Electron Kebebew
Journal:  Clin Cancer Res       Date:  2017-06-09       Impact factor: 12.531

5.  RET polymorphisms might be the risk factors for thyroid cancer.

Authors:  Rui-Xue Huang; Fei Yang
Journal:  Int J Clin Exp Pathol       Date:  2015-05-01

Review 6.  Non-Coding RNAs in Thyroid Cancer.

Authors:  Ranran Zhang; Heather Hardin; Jidong Chen; Zhenying Guo; Ricardo V Lloyd
Journal:  Endocr Pathol       Date:  2016-03       Impact factor: 3.943

7.  Enhanced cytotoxic effect of camptothecin nanosponges in anaplastic thyroid cancer cells in vitro and in vivo on orthotopic xenograft tumors.

Authors:  Casimiro Luca Gigliotti; Benedetta Ferrara; Sergio Occhipinti; Elena Boggio; Giuseppina Barrera; Stefania Pizzimenti; Mirella Giovarelli; Roberto Fantozzi; Annalisa Chiocchetti; Monica Argenziano; Nausicaa Clemente; Francesco Trotta; Caterina Marchiò; Laura Annaratone; Renzo Boldorini; Umberto Dianzani; Roberta Cavalli; Chiara Dianzani
Journal:  Drug Deliv       Date:  2017-11       Impact factor: 6.419

8.  MicroRNA-153 acts as a prognostic marker in gastric cancer and its role in cell migration and invasion.

Authors:  Zhengliang Zhang; Jiangli Sun; Zhenghai Bai; Haijun Li; Shicai He; Rui Chen; Xiangming Che
Journal:  Onco Targets Ther       Date:  2015-02-02       Impact factor: 4.147

9.  3,6-Dihydroxyflavone regulates microRNA-34a through DNA methylation.

Authors:  Xiaoli Peng; Hui Chang; Junli Chen; Qianyong Zhang; Xiaoping Yu; Mantian Mi
Journal:  BMC Cancer       Date:  2017-09-05       Impact factor: 4.430

10.  Novel and Practical Scoring Systems for the Diagnosis of Thyroid Nodules.

Authors:  Ying Wei; Xinrong Zhou; Siyue Liu; Hong Wang; Limin Liu; Renze Liu; Jinsong Kang; Kai Hong; Daowen Wang; Gang Yuan
Journal:  PLoS One       Date:  2016-09-21       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.